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Summary We report the case of an atypical disseminated leishmaniasis with similar clinical
characteristics to post-kala-azar dermal leishmaniasis, an uncommon disease in South America.
This occurred in a Brazilian patient with AIDS, 3 years after the first episode of American visceral
leishmaniasis.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Leishmaniases are endemic in 88 countries, 72 of which are
developing countries. The worldwide prevalence of the dis-
ease is estimated at 12 million cases, with 400 000—600 000
new cases per year for visceral forms.1,2 In Brazil, approxi-
mately 2500—5000 cases are reported each year.3* Corresponding author. Tel.: +55 11 3068 2991;
fax: +55 11 3068 2890.
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doi:10.1016/j.ijid.2009.01.022The genus Leishmania causes a wide spectrum of human
diseases, ranging from self-limited cutaneous to the more
severe diffuse cutaneous and visceral forms, as a conse-
quence of the complex host immunological response.4,5
The causative agent of the American viscerotropic leishma-
niasis in Latin-America is Leishmania (Leishmania) infantum
chagasi included in the subgenus Leishmania.4,5
Despite some differences in cost of treatment, toxicity,
drug resistance, and endemic region, treatment is usually
based on the use of leishmanicidal drugs, principally injec-
tions of pentavalent antimony compounds.1,2,4,6 However,
a significant proportion of the apparently curedPublished by Elsevier Ltd. All rights reserved.
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in India, Nepal, Bangladesh, and East African countries
develop post-kala-azar dermal leishmaniasis (PKDL).7 This
manifestation is a form of cutaneous leishmaniasis char-
acterized by maculopapular or nodular lesions on the face,
limbs or trunk, which appear after a symptom-free period
following the end of visceral leishmaniasis treatment. The
interval between kala-azar and PKDL is estimated as being
months to years in India, but is considerably shorter in
Africa (0—6 months).7—10 The association of Leishmania
(Leishmania) infantum with PKDL is highly unusual
in patients living in Europe11 and rarely present in
patients infected with L. (L.) infantum chagasi in South
America.12,13
Since the onset of the AIDS era, co-infection with HIV and
leishmaniasis has become a high-priority emergent disease
appearing throughout the world.2 In Brazil, both infections
are highly prevalent. In the past, both target populations
were geographically separated. Currently, overlap appears
because of the expansion of leishmaniasis into urban areas
and of HIV infection into rural ones. Despite antiretroviral
therapy, approximately 100 cases of this co-infection are
reported per year in Brazil.14,15
Here, we report an AIDS patient with visceral leishma-
niasis caused by L. (L.) infantum chagasi. After recurrence
and the development of an atypical disseminated leishma-
niasis with PKDL-like appearance of skin lesions, the patient
died.Table 1 Main clinical events
Period (month/year) Clinical event
02/93 Positive for HIV/oral moniliasis
07/96
01/97 ddI intolerance
04/97
05/00
07/01 Cerebral toxoplasmosis
12/02 Hepatitis C
01/04
11/04 Visceral leishmaniasisb
(hepatosplenomegaly/cachexia/ diarrhea/fe
01/05 Ambulatory follow-up
05/05 Visceral leishmaniasis (second episode)
(hepatosplenomegaly/cachexia/diarrhea/fe
12/05 Visceral leishmaniasis (third episode)
(severe anemia/ epistaxis/hepatosplenomeg
10/06 Visceral leishmaniasis (fourth episode)
06/07 Multiple cutaneous lesions on face/thorax
02/08 Death (visceral leishmaniasis)
NA, not available; ATV, atazanavir; ddI, didanosine; EFV, efavirenz; IDV
saquinavir; d4T, stavudine; AZT, zidovudine.
a Antiretroviral treatment was conducted as per the instructions esta
Health Ministry of Brazil.
b Confirmed by bone marrow aspirate examination.
c For 13 days; developed acute pancreatitis.
d Treatment replaced.Case report
The case is that of a 42-year-old male who had migrated to
Sao Paulo City, Brazil from Sa˜o Jose´ do Egito, Pernambuco, an
area of Brazil endemic for visceral leishmaniasis, 27 years
previously. He was found positive for HIV in1993 and had since
undergone several different schedules of antiretroviral ther-
apy. The overall clinical events, including CD4+ Tcell counts,
plasma viral load values, and treatments at each time period
are shown in Table 1. Each event of antiretroviral therapy was
made according to the guidelines of the previously estab-
lished National Program of Sexual Diseases and AIDS of the
Health Ministry of Brazil.16
Even on antiretroviral therapy, his CD4+ levels were found
to have decreased and plasma viral load to have increased in
May 2000. As a result, he had cerebral toxoplasmosis (July
2001) and hepatitis C (December 2002). In January 2004, his
medication was again changed to stavudine, lamivudine and
efavirenz because his CD4+ T cell count was decreased (144
cells/mm3) and his plasma viral load was 812 copies/ml. In
November 2004 he was hospitalized after presenting with
fever, weight loss, diarrhea, epistaxis, and hepatosplenome-
galy (Figure 1A). The diagnosis of visceral leishmaniasis was
confirmed due to the presence of amastigotes in the bone
marrow aspirate. The specific leishmaniasis was treated with
N-methylglucamine antimonate (glucantime, 20 mg/kg/day)
for 13 days, when he developed acute pancreatitis. At this
time, the glucantime was replaced with liposomal ampho-CD4+ T cell
count
(cells/mm3)
Plasma
viral load
(copies/ml)
Treatmenta
385 NA AZT
612 NA AZT/ddI
697 NA AZT/3TC
388 45 000 AZT/3TC
104 290 000 d4T/NVP/SQV
352 200 d4T/3TC/IDV/RTV
168 6860 d4T/3TC/SQV/RTV
144 812 d4T/3TC/EFV
ver)
181 <400 d4T/3TC/EFV—glucantime,c
amphotericin Bd
NA NA d4T/3TC/EFV—glucantime
ver)
72 <400 d4T/3TC/EFV—glucantime
aly)
NA NA d4T/3TC/EFV—liposomal
amphotericin
78 831 d4T/3TC/ATV/RTV—
liposomal amphotericin
66 <50 d4T/3TC/ATV/RTV
09 <50 d4T/3TC/ATV/RTV
, indinavir; 3TC, lamivudine; NVP, nevirapine, RTV, ritonavir; SQV,
blished by the National Program of Sexual Diseases and AIDS of the
Figure 1 Visceral leishmaniasis: clinical and histopathological diagnosis, and species genotyping by PCR. (A) Hepatosplenomegaly.
(B) Histopathological examination of the liver biopsy revealing amastigotes and chronic inflammation (hematoxylin—eosin staining).
Non-pruritic, erythematous maculopapular lesions on (C) face and (D) thorax. (E) Species genotyping by PCR; the RV1—RV2 marker
amplified a 145-bp product from the LT1 fragment of Leishmania donovani complex kDNA minicircles. The amplified PCR product was
analyzed by electrophoresis on 2% agarose gel; lane 1, 100-bp ladder (the lowest band shown is 100 bp); lane 2, patient sample; lane 3,
negative control.
e506 D.C. Jr et al.tericin B (50 mg/day for 3.2 weeks). After hospital discharge,
in ambulatory follow-up, he took glucantime (81 mg) weekly.
Over the course of two years he had three other recurrent
episodes of visceral leishmaniasis (May 2005, December 2005,
and October 2006) and was again treated with glucantime
and liposomal amphotericin B. In October 2006, his antire-
troviral therapy consisted of stavudine, lamivudine, ataza-
navir and ritonavir. His plasma viral load was becoming
undetectable, but his CD4+ T cell count was still gradually
decreasing (78 cells/mm3). In June 2007, his CD4+ T cell
count was 66 cells/mm3 when he developed multiple cuta-
neous lesions on the face and thorax (Figure 1, C and D).
Leishmania infection was also determined by the presence of
amastigotes in histopathological examinations prepared from
liver biopsies (Figure 1B) and skin lesions. The confirmation of
American visceral leishmaniasis and species identification as
L. (L.) infantum chagasi were made by PCR as previously
described.17 The RV1—RV2 marker amplified a 145-bp
sequence from the LT1 fragment of L. (L.) donovani complex
kDNA minicircles18,19 (Figure 1E). He died of disseminated
leishmaniasis in February 2008.
Discussion
Cutaneous manifestations of Leishmania and HIV co-infection
have been described in some patients having visceral leish-
maniasis or as the only clinical manifestation of the disease.
Cutaneous dissemination is generally observed among
severely immunocompromised patients, and lesions tend to
localize symmetrically.11,20 In the present case, the patient
developed visceral recurrent leishmaniasis, despite antire-
troviral, liposomal amphotericin B, and glucantime thera-pies. As a result, he developed an atypical disseminated
leishmaniasis with PKDL-like appearance of skin lesions
(non-itchy maculopapular erythematous lesions on the face
and thorax).
The fact that the patient had a controlled viral load during
the last five years, as determined in plasma, lead us to
suppose that the antiretroviral therapy was efficient in
accordance with the established guidelines.16 However,
the low CD4+ T cell production was constant, suggesting a
lack of immune function, and finally the patient died of
disseminated visceral leishmaniasis.
As the incidence of HIV increases in areas in which Leish-
mania species are endemic, visceral leishmaniasis is being
recognized more frequently as an opportunistic infection in
patients with AIDS. This case also emphasizes the potential
use of PCR to confirm the diagnosis, for Leishmania species
genotyping, and for clinical evaluation and follow-up of HIV
patients undergoing antiretroviral therapy who have pre-
viously had leishmaniasis or patients living in leishmaniasis
endemic areas. In addition, atypical disseminated leishma-
niasis with cutaneous lesions, similar to PKDL, should be
considered in AIDS patients undergoing both antimony com-
pound and antiretroviral treatment.
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